ArticleInternational journal of cancer2017

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Brian H Kushner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.